Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Cash & Equivalents: 2017-2025

Historic Cash & Equivalents for Arcus Biosciences (RCUS) over the last 9 years, with Sep 2025 value amounting to $238.0 million.

  • Arcus Biosciences' Cash & Equivalents rose 18.41% to $238.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $238.0 million, marking a year-over-year increase of 18.41%. This contributed to the annual value of $150.0 million for FY2024, which is 18.11% up from last year.
  • Latest data reveals that Arcus Biosciences reported Cash & Equivalents of $238.0 million as of Q3 2025, which was down 4.03% from $248.0 million recorded in Q2 2025.
  • Over the past 5 years, Arcus Biosciences' Cash & Equivalents peaked at $549.0 million during Q1 2022, and registered a low of $127.0 million during Q4 2023.
  • Moreover, its 3-year median value for Cash & Equivalents was $192.0 million (2025), whereas its average is $195.4 million.
  • As far as peak fluctuations go, Arcus Biosciences' Cash & Equivalents spiked by 479.66% in 2021, and later plummeted by 56.65% in 2023.
  • Arcus Biosciences' Cash & Equivalents (Quarterly) stood at $148.0 million in 2021, then spiked by 39.19% to $206.0 million in 2022, then tumbled by 38.35% to $127.0 million in 2023, then grew by 18.11% to $150.0 million in 2024, then rose by 18.41% to $238.0 million in 2025.
  • Its Cash & Equivalents stands at $238.0 million for Q3 2025, versus $248.0 million for Q2 2025 and $192.0 million for Q1 2025.